Stock Events

Stock Events

NRX Pharmaceuticals 

$2.22
85
-$0.04-1.77% Friday 20:00

Statistics

Day High
2.29
Day Low
2.19
52W High
3.84
52W Low
1.62
Volume
475,855
Avg. Volume
1,055,640
Mkt Cap
62.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.98
-0.51
-0.05
0.42
Expected EPS
0.42
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-50.25MNet Income

Analyst Ratings

38Average Price Target
The highest estimate is 48.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NRXP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical company that competes with NRX Pharmaceuticals in the development and marketing of medications for various therapeutic areas, including mental health.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in developing treatments for disorders that NRX Pharmaceuticals targets, including mental health and other areas.
Merck
MRK
Mkt Cap298.84B
Merck & Co. is involved in the research, development, and marketing of drugs that address conditions similar to those targeted by NRX Pharmaceuticals, making them a direct competitor.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company competes with NRX Pharmaceuticals in the psychiatric and neurological drug market, particularly in areas like depression and bipolar disorder.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the neuroscience and mental health drug market, areas that are of interest to NRX Pharmaceuticals, with a strong portfolio in psychiatric drugs.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb offers a range of products that compete in the therapeutic areas targeted by NRX Pharmaceuticals, including mental health treatments.
Novartis
NVS
Mkt Cap297.32B
Novartis AG competes with NRX Pharmaceuticals through its extensive research and development in therapies for neurological and mental health conditions.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline competes in the pharmaceutical market for mental health medications, a key area of focus for NRX Pharmaceuticals.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries is a global competitor in generic and specialty medicines, including those for neurological and psychiatric conditions that NRX Pharmaceuticals also targets.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is involved in the development of therapies for various diseases, including those in the neurological and psychiatric domain, making them a competitor to NRX Pharmaceuticals.

About

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Show more...
CEO
Dr. Jonathan C. Javitt M.D., M.P.H.
Employees
2
Country
United States
ISIN
US6294442099

Listings

MU
DE
B1Q.MU
XNAS
US
NRXPW
F
DE
B1Q.F
XNAS
US
NRXP

0 Comments

Share your thoughts

FAQ

What is NRX Pharmaceuticals stock price today?▼
The current price of NRXP is $2.22 USD — it has decreased by -1.77% in the past 24 hours. Watch NRX Pharmaceuticals stock price performance more closely on the chart.
What is NRX Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NRX Pharmaceuticals stocks are traded under the ticker NRXP.
Is NRX Pharmaceuticals stock price growing?▼
NRXP stock has risen by +0.91% compared to the previous week, the month change is a +23.33% rise, over the last year NRX Pharmaceuticals has showed a +8.29% increase.
What is NRX Pharmaceuticals market cap?▼
Today NRX Pharmaceuticals has the market capitalization of 62.38M
When is the next NRX Pharmaceuticals earnings date?▼
NRX Pharmaceuticals is going to release the next earnings report on May 19, 2026.
What were NRX Pharmaceuticals earnings last quarter?▼
NRXP earnings for the last quarter are -0.04 USD per share, whereas the estimation was 0.01 USD resulting in a -703.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NRX Pharmaceuticals revenue for the last year?▼
NRX Pharmaceuticals revenue for the last year amounts to 0 USD.
What is NRX Pharmaceuticals net income for the last year?▼
NRXP net income for the last year is -50.25M USD.
How many employees does NRX Pharmaceuticals have?▼
As of April 12, 2026, the company has 2 employees.
In which sector is NRX Pharmaceuticals located?▼
NRX Pharmaceuticals operates in the Health & Wellness sector.
When did NRX Pharmaceuticals complete a stock split?▼
The last stock split for NRX Pharmaceuticals was on April 02, 2024 with a ratio of 1:10.
Where is NRX Pharmaceuticals headquartered?▼
NRX Pharmaceuticals is headquartered in Wilmington, United States.